Ocular Therapeutix (NASDAQ: OCUL) shares AXPAXLI Phase 3 SOL-1 data

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Ocular Therapeutix, Inc. is making investor presentation slides available covering detailed results from its SOL-1 Phase 3 superiority clinical trial of AXPAXLI (also known as OTX-TKI) for treating wet age-related macular degeneration. The slides will be posted on the company’s website Investors section on February 27, 2026, aligned with its presentation at the 49th Macula Society Annual Meeting.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Understanding 8-K Material Events →

02/27/2026 - 04:02 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 27, 2026

OCULAR THERAPEUTIX, INC.

(Exact Name of Company as Specified in Charter)

Delaware		001-36554		20-5560161
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

15 Crosby Drive

Bedford, MA 01730

(Address of Principal Executive Offices) (Zip Code)

Company’s telephone number, including area code: (781) 357-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		OCUL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD Disclosure.

At 4:15 pm Eastern Time on February 27, 2026, Ocular Therapeutix, Inc. (the “Company”) will make available under the Investors section of its corporate website the slides to be presented by the Company at the 49^th Macula Society Annual Meeting on February 27, 2026, regarding the detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI (also known as OTX-TKI), for the treatment of wet age-related macular degeneration.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OCULAR THERAPEUTIX, INC.

Date: February 27, 2026	By:	/s/ Jason S. Robins
		Jason S. Robins
		Interim Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Ocular Therapeutix (OCUL) disclose in this 8-K?

Ocular Therapeutix disclosed it will post investor presentation slides with detailed results from its SOL-1 Phase 3 superiority clinical trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration, coinciding with a presentation at the 49th Macula Society Annual Meeting.

What is AXPAXLI (OTX-TKI) in Ocular Therapeutix’s update?

AXPAXLI, also known as OTX-TKI, is the therapy featured in Ocular Therapeutix’s SOL-1 Phase 3 superiority clinical trial for treating wet age-related macular degeneration, and detailed trial results are being shared in slides on the company’s website Investors section.

What is the SOL-1 Phase 3 trial mentioned by Ocular Therapeutix (OCUL)?

The SOL-1 Phase 3 superiority trial is a clinical study of AXPAXLI (OTX-TKI) for wet age-related macular degeneration. Ocular Therapeutix is providing detailed results from this trial in presentation slides made available to investors on its corporate website.

When will Ocular Therapeutix (OCUL) post the Phase 3 AXPAXLI slides?

Ocular Therapeutix plans to post the SOL-1 Phase 3 AXPAXLI (OTX-TKI) trial slides at 4:15 pm Eastern Time on February 27, 2026, in the Investors section of its corporate website, alongside its presentation at the 49th Macula Society Annual Meeting.

Where can investors access Ocular Therapeutix’s SOL-1 trial slides?

Investors can access the SOL-1 Phase 3 clinical trial slides for AXPAXLI (OTX-TKI) in the Investors section of Ocular Therapeutix’s corporate website, where the company is making the detailed wet age-related macular degeneration study results publicly available.

Filing Exhibits & Attachments

3 documents